BioLine Rx BLRX is estimated to report quarterly loss at $1.06 per share on revenue of $1.48 million. • Champion Homes SKY is projected to report quarterly earnings at $0.76 per share on revenue ...

BioLine Rx BLRX is gearing up to announce its quarterly earnings on Tuesday, 2025-05-27. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Today, the nation stops to honour those who served and died in Australia's military efforts, with Anzac Day services held around the country. Like holding a minute's silence and playing the Last ...

Thrombophob 20gm (Heparin Sodium and Benzyl Nicotinate ointment), worth Rs 2.5 lakh. The drug Thrombophob ointment is a popular brand manufactured by Zydus Healthcare Ltd based in Sikkim. According to ...

BioLine Rx Ltd (NASDAQ:BLRX) executed a significant licensing agreement with AirMed Limited, providing a $10 million upfront payment and potential commercial milestones of $87 million. The company ...

Bioline AgroSciences has announced its acquisition by Eurazeo, a leading European investment group, through its Eurazeo Planetary Boundaries Fund (EPBF). Eurazeo becomes the principal shareholder, ...

Bioline designs, produces and markets biologicals-based services Bioline operates six bio factories across the US, UK, France, Spain and Kenya The fund’s threshold target is €750 million ...

The fund's first investment was Bioline AgroSciences, which designs, produces and markets biological-based solutions to prevent pests destroying crops such as berries, flowers and vegetables.

French investment firm Eurazeo SE has received the competition watchdog’s approval to fully acquire Bioline Agrosciences and its sister company Dudutech Properties for Sh1.1 billion. The ...